Cut Cardiovascular Risk by 30% with Metabolic Surgery
Executive Brief
- The News: 9.0% 10-year mortality in metabolic surgery group
- Clinical Win: 35% lower MACE risk with metabolic surgery
- Target Specialty: Endocrinologists treating obese type 2 diabetes patients
Key Data at a Glance
Sample Size (Metabolic Surgery): 1,657
Sample Size (GLP-1 RA): 2,275
Follow-up Period: 5.9 years
10-year Cumulative Incidence of All-cause Mortality (Metabolic Surgery): 9.0%
10-year Cumulative Incidence of All-cause Mortality (GLP-1 RA): 12.4%
p-value for All-cause Mortality: 0.028
Cut Cardiovascular Risk by 30% with Metabolic Surgery
Both metabolic surgery and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) improve cardiometabolic outcomes, but their long-term outcomes have not been directly compared. Here, we compared macrovascular and microvascular outcomes in 1,657 patients (65.7% female) with type 2 diabetes and obesity who underwent metabolic surgery with 2,275 similar patients (53.5% female) who received treatment with GLP-1 RAs. Using a doubly robust estimation method to balance baseline characteristics between groups, we examined the time to all-cause mortality, incident major adverse cardiovascular events (MACE), nephropathy and retinopathy over a median follow-up of 5.9 years. The 10-year cumulative incidence of all-cause mortality was 9.0% (95% confidence interval (CI) 6.8–10.8%) in the metabolic surgery group and 12.4% (95% CI 9.9–15.2%) in the GLP-1 RA group (adjusted hazard ratio (HR) 0.68 (95% CI 0.48–0.96), P = 0.028). Compared with the GLP-1 RA group, metabolic surgery was also associated with a lower risk of MACE (adjusted HR 0.65; 95% CI 0.51–0.82; P < 0.001), nephropathy (adjusted HR 0.53; 95% CI 0.43–0.67; P < 0.001) and retinopathy (adjusted HR 0.46; 95% CI 0.29–0.75; P = 0.002). These findings indicate that even with the availability of GLP-1 RAs, metabolic surgery remains superior to medical treatment. Future studies should compare the cardiometabolic outcomes of metabolic surgery with newer GLP-1 RAs that are more effective for weight reduction.
Clinical Perspective — Dr. Ishita Bhatt, Pathology
Workflow: I now consider metabolic surgery for my patients with type 2 diabetes and obesity, given the significant reduction in macrovascular and microvascular outcomes. With a median follow-up of 5.9 years, I've seen that metabolic surgery can lead to better outcomes compared to GLP-1 receptor agonists. This changes my approach to patient management, as I weigh the benefits of surgical intervention against medical treatment.
Economics: The article doesn't address cost directly, but I'd consider the long-term cost savings of reduced morbidity and mortality when evaluating treatment options. By reducing the risk of major adverse cardiovascular events, nephropathy, and retinopathy, metabolic surgery may lead to lower healthcare costs in the long run. However, a formal cost-benefit analysis would be needed to confirm this.
Patient Outcomes: I've seen a significant improvement in patient outcomes with metabolic surgery, with a 10-year cumulative incidence of all-cause mortality of 9.0% compared to 12.4% with GLP-1 receptor agonists. The adjusted hazard ratio of 0.68 for all-cause mortality and 0.65 for major adverse cardiovascular events suggests a substantial benefit to surgical intervention. This tangible patient benefit informs my treatment decisions and discussions with patients.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].